Cardiol Therapeutics (TSE:CRDL) Trading Down 4.9% – Here’s What Happened

Cardiol Therapeutics Inc. (TSE:CRDL) was down 4.9% during trading on Wednesday . The stock traded as low as C$1.53 and last traded at C$1.55. Approximately 47,095 shares traded hands during trading, a decline of 56% from the average daily volume of 107,183 shares. The stock had previously closed at C$1.63.

Cardiol Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.48, a quick ratio of 6.84 and a current ratio of 4.39. The stock has a market cap of C$178.67 million, a P/E ratio of -3.97 and a beta of 0.24. The firm’s 50 day moving average is C$1.83 and its 200 day moving average is C$1.55.

Cardiol Therapeutics (TSE:CRDL) last posted its quarterly earnings data on Monday, May 11th. The company reported C($0.10) EPS for the quarter. Analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 EPS for the current year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.